{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T10:28:43Z","timestamp":1778322523014,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T00:00:00Z","timestamp":1623801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>We aimed to evaluate the (a) potential predictors of first biological disease-modifying anti-rheumatic drug (bDMARD) failure and (b) factors associated with failure of multiple therapies in psoriatic arthritis (PsA).<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>We enrolled consecutive PsA patients attending our unit and undergoing bDMARDs during 2004\u20132020. Disease characteristics, previous\/ongoing treatments, comorbidities, and follow-up duration were recorded. Disease activity and functional and clinimetric scores were recorded at baseline and yearly and were compared between switchers and non-switchers, and within switchers according to the reasons for switching. Effectiveness was evaluated over time with descriptive statistics; multivariate Cox and logistic regression models were used to evaluate predictors of response and failure of multiple bDMARDs. Kaplan\u2013Meier curves were used to assess differences in time-to-first bDMARD discontinuation. Infections and adverse events were recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two hundred sixty-four patients were included (117 (44.32%) females, mean age 56\u00a0years, mean PsA duration 15\u00a0years); 117 (44.32%) switched bDMARDs at least once. Switchers were mostly females, with higher Psoriasis Area and Severity Index and worse Health Assessment Questionnaire at baseline. Mean time-to-first bDMARD discontinuation was 72\u00a0months; 2-year and 5-year retention rates were 75% and 60%, respectively. Survival curves for anti-TNF\u03b1\/anti-IL12\/23\/anti-IL17 were similar (<jats:italic>p<\/jats:italic>\u2009=\u20090.66). Main reasons for switching were inefficacy (67.52%) and adverse events (25.7%). Female sex was associated with a higher risk of first bDMARD discontinuation (HR\u2009=\u20092.39; 95% CI: 1.50\u20133.81) and failure of multiple bDMARDs (OR\u2009=\u20091.99; 95% CI: 1.07\u20133.69); initiating therapy before 2015 was protective (HR\u2009=\u20090.40; 95% CI: 0.22\u20130.73).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Survival rate was good for anti-TNF\u03b1 and other bDMARDs. Female sex was a predictor of first bDMARD discontinuation, unlike mechanism of action, comorbidities, and BMI.<jats:table-wrap><jats:table><jats:tbody><jats:tr><jats:td align=\"left\" colspan=\"2\"><jats:bold>Key Points<\/jats:bold><jats:italic>\u2022 Drug survival in PsA patients was confirmed be greater for the first bDMARD administered.<\/jats:italic><jats:italic>\u2022 In case of failure of the first bDMARD, switching\/swapping proved a good treatment option, as reflected by a persistent satisfactory effectiveness with second-line bDMARDs and so subsequent switches.<\/jats:italic><jats:italic>\u2022 Female sex may constitute a predisposing risk factor for flare and therapeutic switches.<\/jats:italic><jats:italic>\u2022 Discontinuation or switching of biologics due to mechanism of action, comorbidities tolerability and BMI did not seem to impact first bDMARD withdrawal.<\/jats:italic><\/jats:td><\/jats:tr><\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p><\/jats:sec>","DOI":"10.1007\/s10067-021-05799-0","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T21:02:43Z","timestamp":1623877363000},"page":"4569-4580","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Predictive factors for switching in patients with psoriatic arthritis undergoing anti-TNF\u03b1, anti-IL12\/23, or anti-IL17 drugs: a 15-year monocentric real-life study"],"prefix":"10.1007","volume":"40","author":[{"given":"Mariagrazia","family":"Lorenzin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusta","family":"Ortolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giacomo","family":"Cozzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Calligaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Favaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Del Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Doria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-8873","authenticated-orcid":false,"given":"Roberta","family":"Ramonda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,16]]},"reference":[{"issue":"Suppl 2","key":"5799_CR1","first-page":"ii14","volume":"64","author":"D Gladman","year":"2005","unstructured":"Gladman D, Antoni C, Mease P, Clegg D, Nash P (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl 2):ii14-7","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"5799_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.autrev.2011.05.022","volume":"10","author":"R Ramonda","year":"2011","unstructured":"Ramonda R, Lo Nigro A, Modesti V, Nalotto L, Musacchio E, Iaccarino L et al (2011) Atherosclerosis in psoriatic arthritis. Autoimmun Rev 10(12):773\u2013778. https:\/\/doi.org\/10.1016\/j.autrev.2011.05.022","journal-title":"Autoimmun Rev"},{"issue":"10","key":"5799_CR3","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1007\/s10067-019-04646-7","volume":"38","author":"A Ortolan","year":"2019","unstructured":"Ortolan A, Lorenzin M, Tadiotto G, Russo FP, Oliviero F, Felicetti M et al (2019) Metabolic syndrome, non-alcoholic fatty liver disease and liver stiffness in psoriatic arthritis and psoriasis patients. Clin Rheumatol 38(10):2843\u20132850. https:\/\/doi.org\/10.1007\/s10067-019-04646-7","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5799_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.jbspin.2014.02.005","volume":"81","author":"R Ramonda","year":"2014","unstructured":"Ramonda R, Puato M, Punzi L, Rattazzi M, Zanon M, Balbi G et al (2014) Atherosclerosis progression in psoriatic arthritis patients despite the treatment with tumor necrosis factor-alpha blockers: a two-year prospective observational study. Joint Bone Spine 81(5):421\u2013425. https:\/\/doi.org\/10.1016\/j.jbspin.2014.02.005","journal-title":"Joint Bone Spine"},{"key":"5799_CR5","doi-asserted-by":"crossref","unstructured":"Ortolan A, Ramonda R, Lorenzin M, Pesavento R, Spinazz\u00e8 A, Felicetti M et al (2020) Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients. Clin Exp Rheumatol. Online ahead of print.","DOI":"10.55563\/clinexprheumatol\/3qiqk3"},{"key":"5799_CR6","doi-asserted-by":"publisher","unstructured":"Ortolan A, Lorenzin M, Felicetti M, Ramonda R (2020) Do obesity and overweight influence disease activity measures in axial spondyloarthritis? A systematic review and meta-analysis. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.24416. Online ahead of print.","DOI":"10.1002\/acr.24416"},{"issue":"1","key":"5799_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G (2018) Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48(1):28\u201334. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.003","journal-title":"Semin Arthritis Rheum"},{"key":"5799_CR8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40265-014-0191-y","volume":"74","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Armstrong AW (2014) Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74:423\u2013441","journal-title":"Drugs"},{"issue":"6","key":"5799_CR9","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M et al (2020) EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 79(6):700\u2013712. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217159","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5799_CR10","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Acosta L, Felquer M et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u20131071. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"5799_CR11","first-page":"991","volume":"35","author":"A Marchesoni","year":"2017","unstructured":"Marchesoni A, Olivieri I, Salvarani C, Pipitone N, D\u2019Angelo S, Mathieu A et al (2017) Recommendations for the use of biologics and other novel drugs in the treatment of psoriatic arthritis: 2017 update from the Italian Society of Rheumatology. Clin Exp Rheumatol 35(6):991\u20131010","journal-title":"Clin Exp Rheumatol"},{"key":"5799_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.semarthrit.2010.07.004","volume":"40","author":"I Saougou","year":"2011","unstructured":"Saougou I, Markatseli TE, Papagoras C, Voulgari PV, Alamanos Y, Drosos AA (2011) Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study. Semin Arthritis Rheum 40:398\u2013406","journal-title":"Semin Arthritis Rheum"},{"key":"5799_CR13","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"PJ Mease","year":"2004","unstructured":"Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P et al (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50:2264\u20132272","journal-title":"Arthritis Rheum"},{"key":"5799_CR14","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/art.20967","volume":"52","author":"C Antoni","year":"2005","unstructured":"Antoni C, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U et al (2005) Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 52:1227\u20131236","journal-title":"Arthritis Rheum"},{"key":"5799_CR15","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1002\/art.21306","volume":"52","author":"PJ Mease","year":"2005","unstructured":"Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:3279\u20133289","journal-title":"Arthritis Rheum"},{"key":"5799_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","volume":"73","author":"PJ Mease","year":"2014","unstructured":"Mease PJ, Fleischmann R, Deodhar AA, Wollenhaupt J, Khraishi M, Kielar D et al (2014) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis 73:48\u201355","journal-title":"Ann Rheum Dis"},{"key":"5799_CR17","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1002\/art.24403","volume":"60","author":"A Kavanaugh","year":"2009","unstructured":"Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J et al (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60:976\u2013986","journal-title":"Arthritis Rheum"},{"key":"5799_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1136\/ard.2007.073544","volume":"67","author":"LE Kristensen","year":"2008","unstructured":"Kristensen LE, G\u00fclfe A, Saxne T, Geborek P (2008) Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis 67:364\u2013369","journal-title":"Ann Rheum Dis"},{"key":"5799_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.3389\/fphar.2019.00872","volume":"10","author":"LI Sakkas","year":"2019","unstructured":"Sakkas LI, Zafiriou E, Bogdanos DP (2019) Mini review: New treatments in psoriatic arthritis focus on the IL-23\/17 axis. Focus on the IL-23\/17 axis. Front Pharmacol 10:872. https:\/\/doi.org\/10.3389\/fphar.2019.00872","journal-title":"Front Pharmacol"},{"key":"5799_CR20","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK, PSUMMIT 1 Study Group (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382:780\u2013789","journal-title":"Lancet"},{"issue":"1","key":"5799_CR21","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/acr2.1109","volume":"2","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S, FUTURE 1 study group (2020) Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: final 5-year results from the phase 3 FUTURE 1 Study. ACR Open Rheumatol 2(1):18\u201325. https:\/\/doi.org\/10.1002\/acr2.1109","journal-title":"ACR Open Rheumatol"},{"key":"5799_CR22","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","volume":"73","author":"A Kavanaugh","year":"2014","unstructured":"Kavanaugh A, Mease PJ, Gomez-Reino JJ, Adebajo AO, Wollenhaupt J, Gladman DD et al (2014) Treatment of psoriatic arthritis, in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73:1020\u20131026","journal-title":"Ann Rheum Dis"},{"issue":"100601","key":"5799_CR23","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.curtheres.2020.100601.eCollection","volume":"93","author":"DD Gladman","year":"2020","unstructured":"Gladman DD, Orbai AM, Gomez-Reino J, Chang-Douglass S, Leoncini E, Burton HE et al (2020) Network meta-analysis of tofacitinib, biologic disease-modifying antirheumatic drugs, and apremilast for the treatment of psoriatic arthritis. Curr Ther Res Clin Exp 93(100601):2020. https:\/\/doi.org\/10.1016\/j.curtheres.2020.100601.eCollection","journal-title":"Curr Ther Res Clin Exp"},{"issue":"4","key":"5799_CR24","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/art.30176","volume":"63","author":"P Mease","year":"2011","unstructured":"Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP et al (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63(4):939\u2013948","journal-title":"Arthritis Rheum"},{"issue":"6","key":"5799_CR25","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s40265-016-0557-4","volume":"76","author":"E Lubrano","year":"2016","unstructured":"Lubrano E, Perrotta FM (2016) Beyond TNF inhibitors: new pathways and emerging treatments for psoriatic arthritis. Drugs 76(6):663\u2013673. https:\/\/doi.org\/10.1007\/s40265-016-0557-4","journal-title":"Drugs"},{"issue":"3","key":"5799_CR26","doi-asserted-by":"publisher","first-page":"R72","DOI":"10.1186\/ar1941","volume":"8","author":"L Carmona","year":"2006","unstructured":"Carmona L, Gomez-Reino JJ, Group B (2006) Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. Arthritis Res Ther. 8(3):R72. https:\/\/doi.org\/10.1186\/ar1941","journal-title":"Arthritis Res Ther."},{"issue":"10","key":"5799_CR27","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/acr.20258","volume":"62","author":"LE Kristensen","year":"2010","unstructured":"Kristensen LE, Karlsson JA, Englund M, Petersson IF, Saxne T, Geborek P (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 62(10):1362\u20131369. https:\/\/doi.org\/10.1002\/acr.20258","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"5799_CR28","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1136\/ard.2010.139774","volume":"70","author":"MM Soliman","year":"2011","unstructured":"Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, British Society for Rheumatology Biologics Register (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(4):583\u2013589. https:\/\/doi.org\/10.1136\/ard.2010.139774","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"5799_CR29","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/art.37876","volume":"65","author":"B Glintborg","year":"2013","unstructured":"Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG et al (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 65(5):1213\u20131223. https:\/\/doi.org\/10.1002\/art.37876","journal-title":"Arthritis Rheum"},{"issue":"4","key":"5799_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","volume":"36","author":"LR Harrold","year":"2017","unstructured":"Harrold LR, Stolshek BS, Rebello S, Collier DH, Mutebi A, Wade SW et al (2017) Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. Clin Rheumatol 36(4):895\u2013901. https:\/\/doi.org\/10.1007\/s10067-017-3593-x","journal-title":"Clin Rheumatol"},{"issue":"8","key":"5799_CR31","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, CASPAR Study Group (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"Suppl 11","key":"5799_CR32","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1002\/acr.20577","volume":"63","author":"PJ Mease","year":"2011","unstructured":"Mease PJ (2011) Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander\/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res (Hoboken) 63(Suppl 11):S64-85. https:\/\/doi.org\/10.1002\/acr.20577","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"5799_CR33","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"issue":"4","key":"5799_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/0394632015599446","volume":"28","author":"M Lorenzin","year":"2015","unstructured":"Lorenzin M, Ortolan A, de Hooge M, Frallonardo P, Piccoli A, Cozzi F et al (2015) Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: a single-center retrospective study. Int J Immunopathol Pharmacol 28(4):479\u2013487. https:\/\/doi.org\/10.1177\/0394632015599446","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1415","key":"5799_CR35","first-page":"34","volume":"128","author":"K Ip","year":"2015","unstructured":"Ip K, Hartley L, Solanki K, White D (2015) Retention on anti-tumour necrosis factor therapy: the Waikato experience. N Z Med J 128(1415):34\u201340","journal-title":"N Z Med J"},{"issue":"6","key":"5799_CR36","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T et al (2017) Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum 46(6):732\u2013739. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.09.005","journal-title":"Semin Arthritis Rheum"},{"key":"5799_CR37","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12891-015-0620-4","volume":"16","author":"M Lorenzin","year":"2015","unstructured":"Lorenzin M, Ortolan A, Frallonardo P, Oliviero F, Punzi L, Ramonda R (2015) Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord 16:166. https:\/\/doi.org\/10.1186\/s12891-015-0620-4","journal-title":"BMC Musculoskelet Disord"},{"key":"5799_CR38","doi-asserted-by":"publisher","unstructured":"Soubrier A, Bele-Philippe P, Cortet B, Ramdane-Sebbane N, Bacle-Boutry MA, Lemeunier L, et al (2015). Treatment response, drug survival and safety of anti-tumour necrosis factor \u03b1 therapy in 193 patients with psoriatic arthritis: a twelve-year \u201creal life\u201d experience. Joint Bone Spine 82(1):31-37. http:\/\/www.sciencedirect.com\/science\/article\/pii\/S1297319X14001912. https:\/\/doi.org\/10.1016\/j.jbspin.2014.08.001","DOI":"10.1016\/j.jbspin.2014.08.001"},{"issue":"4","key":"5799_CR39","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s40268-017-0215-7","volume":"17","author":"L Costa","year":"2017","unstructured":"Costa L, Perricone C, Chimenti M, Del Puente A, Caso P, Peluso R et al (2017) Switching between biological treatments in psoriatic arthritis: a review of the evidence. Drugs R D 17(4):509\u2013522. https:\/\/doi.org\/10.1007\/s40268-017-0215-7","journal-title":"Drugs R D"},{"key":"5799_CR40","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","volume":"72","author":"KM Fagerli","year":"2013","unstructured":"Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Kalstad S, R\u00f8devand E et al (2013) Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 72:1840\u20131844","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"5799_CR41","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/ar1881","volume":"8","author":"JJ Gomez-Reino","year":"2006","unstructured":"Gomez-Reino JJ, Carmona L, BIOBADASER Group (2006) Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 8(1):R29. https:\/\/doi.org\/10.1186\/ar1881","journal-title":"Arthritis Res Ther"},{"key":"5799_CR42","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59:234\u2013240","journal-title":"Arthritis Rheum"},{"key":"5799_CR43","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP (2009) Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. Arthritis Res Ther 11:R52","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"5799_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3899\/jrheum.150744","volume":"43","author":"LE Kristensen","year":"2016","unstructured":"Kristensen LE, Lie E, Jacobsson LT, Christensen R, Mease PJ, Bliddal H et al (2016) Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from Southern Sweden. J Rheumatol 43(1):81\u201387. https:\/\/doi.org\/10.3899\/jrheum.150744","journal-title":"J Rheumatol"},{"issue":"4","key":"5799_CR45","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1093\/rheumatology\/keq377","volume":"50","author":"J Paccou","year":"2011","unstructured":"Paccou J, Solau-Gervais E, Houvenagel E, Salleron J, Luraschi H, Philippe P et al (2011) Efficacy in current practice of switching between anti-tumour necrosis factor- \u03b1 agents in spondyloarthropathies. Rheumatology (Oxford) 50(4):714\u2013720. https:\/\/doi.org\/10.1093\/rheumatology\/keq377","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"5799_CR46","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1007\/s10067-016-3425-4","volume":"35","author":"SM Reddy","year":"2016","unstructured":"Reddy SM, Crean S, Martin AL, Burns MD, Palmer JB (2016) Real-world effectiveness of anti-TNF switching in psoriatic arthritis: a systematic review of the literature. Clin Rheumatol 35(12):2955\u20132966. https:\/\/doi.org\/10.1007\/s10067-016-3425-4","journal-title":"Clin Rheumatol"},{"issue":"6","key":"5799_CR47","doi-asserted-by":"publisher","first-page":"490","DOI":"10.3109\/03009742.2012.698393","volume":"41","author":"V Modesti","year":"2012","unstructured":"Modesti V, Ramonda R, Ortolan A, Lorenzin M, Lo Nigro A, Frallonardo P et al (2012) Infection relapse in spondyloarthritis treated with biological drugs: a single-centre study. Scand J Rheumatol 41(6):490\u2013491. https:\/\/doi.org\/10.3109\/03009742.2012.698393","journal-title":"Scand J Rheumatol"},{"key":"5799_CR48","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","volume":"54","author":"F Behrens","year":"2015","unstructured":"Behrens F, Ca\u00f1ete JD, Olivieri I, van Kuijk AW, McHugh N, Combe B (2015) Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature. Rheumatology (Oxford) 54:915\u2013926","journal-title":"Rheumatology (Oxford)"},{"key":"5799_CR49","doi-asserted-by":"publisher","first-page":"192","DOI":"10.3109\/03009742.2014.962081","volume":"44","author":"F Iannone","year":"2015","unstructured":"Iannone F, Lopriore S, Bucci R, Scioscia C, Anelli MG, Notarnicola A et al (2015) Two-year survival rates of anti-TNF-a therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA. Scand J Rheumatol 44:192\u2013199","journal-title":"Scand J Rheumatol"},{"key":"5799_CR50","doi-asserted-by":"publisher","unstructured":"Ramos Pinheiro R, Brasileiro A, Brito A, Barreto P, Pinheiro S (2016) SAT0412 Biological therapy in psoriatic arthritis (PSA): differences between switchers and non-switchers. Ann Rheum Dis 75(Suppl 2):819. http:\/\/ard.bmj.com\/content\/75\/Suppl_2\/819.1.abstract. https:\/\/doi.org\/10.1136\/annrheumdis-2016-eular.3019","DOI":"10.1136\/annrheumdis-2016-eular.3019"},{"issue":"7","key":"5799_CR51","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1093\/rheumatology\/kez505","volume":"59","author":"F Iannone","year":"2020","unstructured":"Iannone F, Nivuori M, Fornaro M, Venerito V, Cacciapaglia F, Lopalco G (2020) Comorbid fibromyalgia impairs the effectiveness of biologic drugs in patients with psoriatic arthritis. Rheumatology (Oxford) 59(7):1599\u20131606. https:\/\/doi.org\/10.1093\/rheumatology\/kez505","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"5799_CR52","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.semarthrit.2017.01.008","volume":"47","author":"F Iannone","year":"2017","unstructured":"Iannone F, Santo L, Anelli MG, Bucci R, Semeraro A, Quarta L, D\u2019Onofrio F, Marsico A, Carlino G, Casilli O, Cacciapaglia F, Zuccaro C, Falappone PC, Cantatore FP, Muratore M, Lapadula G (2017) Golimumab in real-life settings: 2 years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. Semin Arthritis Rheum. 47(1):108\u2013114. https:\/\/doi.org\/10.1016\/j.semarthrit.2017.01.008","journal-title":"Semin Arthritis Rheum."}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05799-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05799-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,31]],"date-time":"2022-12-31T11:59:33Z","timestamp":1672487973000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05799-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,16]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["5799"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05799-0","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,16]]},"assertion":[{"value":"26 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RR and AD has received honoraria and speaker fees from Novartis, AbbVie, Pfizer, MSD, and Janssen. The other authors declare no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}